<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Miserez AR</dc:creator>
  <dc:creator>Günes I</dc:creator>
  <dc:creator>Müller-Brand J</dc:creator>
  <dc:creator>Walther E</dc:creator>
  <dc:creator>Fridrich R</dc:creator>
  <dc:creator>Mäcke H</dc:creator>
  <dc:date>1991</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">A new tumour marker, mucin-like carcinoma-associated antigen (MCA), was evaluated in 176 breast cancer patients classified either as free of tumour (NED, n = 141) or as having metastases (PD, n = 35). During the 5 year follow-up, 842 measurements of MCA and 363 measurements of CA 15-3 were done. MCA levels were significantly increased in the PD group (P = 0.0001) but not in the NED group. The sensitivities of the MCA and the CA 15-3 assays were 84% and 78% and the specificities were 81% and 78%, respectively. The negative predictive value of 97% for MCA was significantly higher (P = 0.0001) than the 88% for CA 15-3. Thus the MCA enzyme immunoassay is at least equivalent to the CA 15-3 test and is recommended in the assessment of metastatic spread or tumour recurrence in breast cancer patients.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/233065</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/0277-5379(91)90468-s</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/1827273</dc:relation>
  <dc:source>European journal of cancer (Oxford, England : 1990). - 1991</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Antigens, Neoplasm</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Antigens, Tumor-Associated, Carbohydrate</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Biomarkers, Tumor</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Breast Neoplasms</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Follow-Up Studies</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Immunoenzyme Techniques</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Neoplasm Metastasis</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Sensitivity and Specificity</dc:subject>
  <dc:title xmlns:ns11="xml" ns11:lang="en">Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>